What is the primary action of PCP on receptors?

The primary action of PCP, or phencyclidine, on receptors is that it binds to glutamate receptors, specifically the NMDA (N-methyl-D-aspartate) subtype. By binding to these receptors, PCP acts as a non-competitive antagonist which inhibits the action of glutamate, the primary excitatory neurotransmitter in the brain. This action leads to alterations in synaptic transmission, influencing perceptions and cognition.

This interaction with glutamate receptors is particularly significant as it can contribute to the dissociative and hallucinogenic effects often associated with PCP use. By impeding normal synaptic communication, PCP can disrupt sensory processing and perception, resulting in the characteristic experiences reported by users.

Other options, while related to various neurochemical pathways, do not accurately represent the most critical receptor interaction that defines PCP's pharmacological profile.